These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24978675)

  • 1. PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy.
    Cusano NE; Rubin MR; McMahon DJ; Irani D; Anderson L; Levy E; Bilezikian JP
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3694-9. PubMed ID: 24978675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of PTH(1-84) on quality of life in hypoparathyroidism.
    Cusano NE; Rubin MR; McMahon DJ; Irani D; Tulley A; Sliney J; Bilezikian JP
    J Clin Endocrinol Metab; 2013 Jun; 98(6):2356-61. PubMed ID: 23596139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy.
    Tabacco G; Tay YD; Cusano NE; Williams J; Omeragic B; Majeed R; Almonte MG; Rubin MR; Bilezikian JP
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2748-2756. PubMed ID: 30776291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTH(1-34) for Surgical Hypoparathyroidism: A 2-Year Prospective, Open-Label Investigation of Efficacy and Quality of Life.
    Palermo A; Santonati A; Tabacco G; Bosco D; Spada A; Pedone C; Raggiunti B; Doris T; Maggi D; Grimaldi F; Manfrini S; Vescini F
    J Clin Endocrinol Metab; 2018 Jan; 103(1):271-280. PubMed ID: 29099939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTH 1-34 Replacement Therapy Has Minimal Effect on Quality of Life in Patients With Hypoparathyroidism.
    Roszko KL; Hu TY; Guthrie LC; Brillante BA; Smith M; Collins MT; Gafni RI
    J Bone Miner Res; 2022 Jan; 37(1):68-77. PubMed ID: 34585778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTH(1-34) for Surgical Hypoparathyroidism: A Prospective, Open-Label Investigation of Efficacy and Quality of Life.
    Santonati A; Palermo A; Maddaloni E; Bosco D; Spada A; Grimaldi F; Raggiunti B; Volpe R; Manfrini S; Vescini F;
    J Clin Endocrinol Metab; 2015 Sep; 100(9):3590-7. PubMed ID: 26196949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial.
    Sikjaer T; Rolighed L; Hess A; Fuglsang-Frederiksen A; Mosekilde L; Rejnmark L
    Osteoporos Int; 2014 Jun; 25(6):1717-26. PubMed ID: 24687385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism.
    Khan AA; Rejnmark L; Rubin M; Schwarz P; Vokes T; Clarke B; Ahmed I; Hofbauer L; Marcocci C; Pagotto U; Palermo A; Eriksen E; Brod M; Markova D; Smith A; Pihl S; Mourya S; Karpf DB; Shu AD
    J Clin Endocrinol Metab; 2022 Jan; 107(1):e372-e385. PubMed ID: 34347093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of Life in Hypoparathyroidism.
    Vokes TJ
    Endocrinol Metab Clin North Am; 2018 Dec; 47(4):855-864. PubMed ID: 30390818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism.
    Rubin MR; Dempster DW; Sliney J; Zhou H; Nickolas TL; Stein EM; Dworakowski E; Dellabadia M; Ives R; McMahon DJ; Zhang C; Silverberg SJ; Shane E; Cremers S; Bilezikian JP
    J Bone Miner Res; 2011 Nov; 26(11):2727-36. PubMed ID: 21735476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid hormone 1-84 alters circulating vascular endothelial growth factor levels in hypoparathyroidism.
    Cusano NE; Rubin MR; Zhang C; Anderson L; Levy E; Costa AG; Irani D; Bilezikian JP
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E2025-8. PubMed ID: 25137422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism.
    Vokes TJ; Mannstadt M; Levine MA; Clarke BL; Lakatos P; Chen K; Piccolo R; Krasner A; Shoback DM; Bilezikian JP
    J Clin Endocrinol Metab; 2018 Feb; 103(2):722-731. PubMed ID: 29099947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoparathyroidism: changes in brain structure, cognitive impairment, and reduced quality of life.
    Sikjaer T; Eskildsen SF; Underbjerg L; Østergaard L; Rejnmark L; Evald L
    J Bone Miner Res; 2024 Aug; 39(7):855-866. PubMed ID: 38648280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life in hypoparathyroidism.
    Vokes T
    Bone; 2019 Mar; 120():542-547. PubMed ID: 30261328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of parathyroid hormone in hypoparathyroidism.
    Cusano NE; Rubin MR; Irani D; Sliney J; Bilezikian JP
    J Endocrinol Invest; 2013 Dec; 36(11):1121-7. PubMed ID: 24445125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTH level might be associated with impaired quality of life in patients with nonsurgical hypoparathyroidism.
    Song A; Chen S; Yang Y; Jiang Y; Jiang Y; Li M; Xia W; Wang O; Xing X
    J Endocrinol Invest; 2023 Dec; 46(12):2471-2479. PubMed ID: 37266827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.
    Mannstadt M; Clarke BL; Vokes T; Brandi ML; Ranganath L; Fraser WD; Lakatos P; Bajnok L; Garceau R; Mosekilde L; Lagast H; Shoback D; Bilezikian JP
    Lancet Diabetes Endocrinol; 2013 Dec; 1(4):275-83. PubMed ID: 24622413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effect of rhPTH(1-84) on Bone Mineral Density and Trabecular Bone Score in Hypoparathyroidism and Postmenopausal Osteoporosis.
    Cipriani C; Pepe J; Silva BC; Rubin MR; Cusano NE; McMahon DJ; Nieddu L; Angelozzi M; Biamonte F; Diacinti D; Hans D; Minisola S; Bilezikian JP
    J Bone Miner Res; 2018 Dec; 33(12):2132-2139. PubMed ID: 30088838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
    Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
    Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of hypoparathyroidism with intact parathyroid hormone.
    Rubin MR; Sliney J; McMahon DJ; Silverberg SJ; Bilezikian JP
    Osteoporos Int; 2010 Nov; 21(11):1927-34. PubMed ID: 20094706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.